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A B S T R A C T 
Diabetes mellitus has become a global epidemic. It 
causes significant macrovascular complications such 
as coronary artery disease, peripheral artery disease, 
and stroke; as well as microvascular complications 
such as retinopathy, nephropathy, and neuropathy. 
Diabetic retinopathy is known to be the leading 
cause of blindness in the working-age population 
and may be asymptomatic until vision loss occurs. 
Screening for diabetic retinopathy has been shown 
to reduce blindness by timely detection and effective 
laser treatment. Diabetic retinopathy screening 
is being done worldwide either as a national 
screening programme or hospital-based project or 
as a community-based screening programme. In this 
article, we review different methods of screening 
including grading used to detect the severity of sight-
threatening retinopathy and the newer screening 
methods. This review also includes the method of 
systematic screening being carried out in Hong 
Kong, a system that has helped to identify diabetic 
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Introduction
Diabetes mellitus (DM) is becoming a global 
epidemic. In 2010, the World Health Organization 
(WHO) estimated that the global prevalence of 
DM is approximately 6.4% or 280 million people 
worldwide.1 The figures from 2014 are even more 
alarming: approximately 347 million people globally 
are diagnosed to have DM.2 Sedentary lifestyles, lack 
of physical activity, obesity, and lack of awareness 
have contributed to an increased prevalence of DM, 
particularly in developing countries.2
 Diabetes mellitus is a chronic disease 
characterised by hyperglycaemia. Of the two types 
of DM, type 1 (insulin-dependent or juvenile type) 
is characterised by a total lack of insulin due to 
destruction of islets of Langerhans in the pancreas, 
due to an autoimmune process the cause of which 
may be unknown, and is not preventable with 
current knowledge.3,4 Type 2 DM, the more common 
type (non–insulin-dependent or adult-onset) 
characterised by resistance to the action of insulin 
and failure of insulin production, usually occurs due 
to excess body weight and lack of physical activity 
and is preventable.3,4
 Diabetes mellitus causes both macrovascular 
complications such as coronary artery disease, 
peripheral arterial disease, and stroke; and 
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microvascular complications such as diabetic 
nephropathy, neuropathy, and retinopathy.5 Diabetic 
retinopathy (DR) is one of the most common 
microvascular complications and one of the most 
common causes of blindness in populations of 
working age (20-70 years). While certain risk factors 
for DR, like the type and duration of DM, cannot be 
modified, control of other modifiable risk factors such 
as glycaemic control (haemoglobin A1c [HbA1c]), 
hypertension, and hyperlipidaemia is effective and 
essential to reduce DR-related blindness.6-9 
 Diabetic retinopathy consists of the early non-
proliferative diabetic retinopathy (NPDR) stage, 
which can be mild, moderate, or severe; the advanced 
stage as proliferative DR (PDR); and maculopathy or 
diabetic macular oedema. Vision loss in DR occurs 
mainly due to macular oedema and PDR. Some 
studies consider PDR and diabetic macular oedema 
or diabetic maculopathy to be sight-threatening DR 
(STDR) while some other studies include moderate-
to-severe NPDR additionally within the category 
of STDR. Blindness caused by DR is preventable. 
Since DR is usually asymptomatic, early detection 
and timely treatment are essential to prevent 
blindness.10-12 The Diabetic Retinopathy Study and 
The Early Treatment Diabetic Retinopathy Study 
(ETDRS) showed the effectiveness of scatter laser 
REVIEW ARTICLE
retinopathy among all attendees in public primary 
care clinics using a Hong Kong–wide public patients’ 
database. 
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photocoagulation in patients with severe NPDR 
and PDR, and focal laser treatment in patients with 
diabetic macular oedema.10-12 Diabetic macular 
oedema is associated with the breakdown of the 
blood-retinal barrier. Inflammation plays a significant 
role and is mediated by multiple cytokines including 
inflammatory cytokines and vascular endothelial 
growth factor (VEGF).13 Several clinical trials have 
demonstrated the effectiveness of anti-VEGF drugs 
(such as ranibizumab, bevacizumab, pegaptanib and 
aflibercept) in restoring the integrity of the blood-
retinal barrier and effectively reducing diabetic 
macular oedema and improving vision.14 
 Blindness due to DR has important 
implications for the individual and is a huge socio-
economic burden on the health care system and 
society.15,16 Although new treatments with anti-
VEGF therapy for diabetic macular oedema and PDR 
can be very effective, they are very costly considering 
most people need maintenance treatment over some 
months and years.16 Additionally, chronic cases do 
not respond well to anti-VEGF therapy. 
 The WHO recommends that screening should 
be done for any condition that is an important 
health problem, has an effective treatment that can 
be delivered early, usually before symptoms of the 
condition are apparent, when facilities for diagnosis 
and treatment are available, when screening is 
feasible and cost-effective, and when subjects can 
be followed up longitudinally.17 Diabetic retinopathy 
fulfils most of these criteria and some studies have 
shown that screening can reduce the rate of blindness 
due to DR.18,19
 Since photocoagulation is effective to treat 
retinopathy and prevent blindness, it has been 
considered unethical to conduct a randomised 
controlled trial of screening versus no screening.20 
Therefore, few studies have examined the cost-
effectiveness of screening for DR directly and 
most have used computer-based cost-effectiveness 
models to simulate the experience of cohorts of 
diabetic patients.20,21 Such studies have calculated 
the cost-effectiveness of screening and treatment in 
terms of cost per quality-adjusted life year gained, 
sight year saved, or case of blindness avoided.21,22 
One study carried out in Hong Kong showed that 
systematic screening at no charge to the subject is 
more cost-effective from the societal perspective 
than screening with a small co-payment.23
 The important measures to prevent vision 
loss due to DR therefore include: (1) early detection 
of retinopathy by some form of screening, (2) 
subsequent monitoring of the condition with regular 
fundus examination, and (3) timely and effective 
laser treatment when deemed necessary. 
 Screening of DR is carried out at most 
places throughout the world, but there is no single 
recommended method that is suitable for every 
country. The DR classification and grading method, 
particularly for STDR, has minor differences across 
different countries too. The aim of this paper was to 
review the methods of screening for DR from both a 
global and local perspective. 
History of diabetic retinopathy 
screening
In 1989, the St Vincent Declaration in Europe 
aimed to reduce DM-related blindness by one third 
in 5 years.24 The Diabetes 2000 programme of the 
American Academy of Ophthalmology (AAO) was 
implemented to promote screening and treatment 
for DR.25 The English national screening programme 
(ENSP) started systematic DR screening in 2003 and 
aimed to reduce blindness by 40% within 5 years.26,27 
Systematic screening means that every eligible 
person is contacted and offered screening regularly 
and every effort is made to screen the whole group 
at risk. This usually requires a register of all those 
with DM and the maintenance of active contact 
with them. In 2004, 15 years after the St Vincent 
Declaration, the Liverpool declaration aimed to 
reduce DR-related blindness further by ensuring 
that systematic screening reached at least 80% of 
the diabetic population in all European countries. 
As a result, there is now universal access to laser 
therapy in these countries.28 In South-East Asia, 
Thailand has launched the new Thailand Healthy 
Lifestyle Strategy Plan (2011-2020) to decrease the 
prevalence, complications, and disability of five 
major non-communicable diseases including DM 
and is now introducing a mobile eye care project to 
enable people from rural communities to have access 
to DM screening.29,30 
 In order to ensure standardisation and quality 
of DR screening, guidelines have been developed 
by national organisations such as the American 
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Diabetes Association (ADA), the AAO, and the 
ENSP, and many screening programmes are now 
being carried out worldwide.25,26,30,31
Recommendations for diabetic 
retinopathy screening 
According to ADA and AAO, adults and children of 
≥10 years of age who had type 1 DM should have 
an initial and comprehensive eye examination by an 
ophthalmologist or optometrist within 5 years of 
the diagnosis. Similarly, type 2 DM patients should 
undergo DR screening within 5 years of the diagnosis. 
An initial comprehensive eye examination should 
include dilated fundal examination and follow-
up examinations at least yearly thereafter.25,28,31 In 
the presence of any retinopathy (NPDR, PDR, or 
macular oedema), referral to an ophthalmologist 
is required and more frequent examinations are 
recommended. Pregnant women with pre-existing 
DM should undergo dilated fundus examination in 
the first trimester with close follow-up throughout 
pregnancy and for 1 year postpartum.25 Women 
who develop gestational DM do not require an 
eye examination during pregnancy and are not at 
increased risk of developing DR during pregnancy.25 
Patients with mental and physical disability are 
not excluded from DR screening; ENSP has special 
provision for such groups.32 
 Many of the current guidelines, such as AAO 
and ENSP, recommend annual screening for DR.25,31,32 
Iceland is one of the pioneers in DR screening and 
introduced a risk-adjusted screening interval for DR. 
The Icelandic model adjusts the screening interval 
from 6 months up to 60 months according to the 
individual risk of STDR taking into account the level 
of HbA1c, systolic blood pressure, type of DM, stage 
of DR, gender, and duration of DM.33 Screening 
intervals in the Icelandic model could therefore be 
more variable than the fixed intervals in the AAO or 
ENSP in the UK.33,34
Types of diabetic retinopathy 
screening
Opportunistic versus systematic screening
Opportunistic screening is sporadic and occurs 
when a test is offered by a doctor or health care 
professional or when the patient asks the doctor 
for the test. Opportunistic screening may not be 
checked for quality assurance and may not include all 
those at risk. In contrast and as previously described, 
systematic screening consists of quality-assured pre-
determined screening processes that include the 
active identification of those at risk, maintenance of 
a register of eligible subjects, and invitation to attend 
the screening programme. Everyone who participates 
in the systematic screening undergoes the same 
method of screening. The selection, invitation, and 
follow-up processes are determined in advance and 
constitute a system that provides feedback and/or 
referral with call and recall for screening at specified 
intervals. 
 Historically, opportunistic screening has been 
done. Systematic screening, which includes the 
whole population at risk in its target group, ensures 
much better coverage of DM patients. 
Methods used for screening
Screening for DR has been performed using different 
methods. This includes direct ophthalmoscopy, 
dilated stereoscopic fundoscopy, fundus analogue 
photography and now, more commonly, the use 
of digital photography with wide-angle imaging. 
The digital fundus photography can be performed 
with pupil dilatation (mydriatic) or without 
pupil dilatation (non-mydriatic) and also with a 
stereoscopic or non-stereoscopic technique. Non-
mydriatic fundus cameras have been commonly 
employed in DR screening as they have the 
advantage of not requiring pupil dilatation and can 
capture a wide angle of the retina. In the presence of 
media opacity such as cataract, however, the image 
quality of non-mydriatic cameras is less satisfactory 
and may lead to ungradable images. For this reason, 
mydriatic fundus photography is preferred in the 
diabetic population given that cataract is more 
prevalent as it has the advantage of having a lower 
percentage of ungradable images due to media 
opacity. Nevertheless, pupil dilatation is more time-
consuming and carries a small risk of precipitating 
an acute angle-closure glaucoma attack. 
 The previously accepted gold standard for 
DR screening is dilated seven-field 30° stereoscopic 
fundus photographs with grading by experienced 
readers using the recommended ETDRS process 
(Fig 1).35 This procedure remains the gold standard 
for academic research but is seldom adopted for 
population screening because it is time-consuming. 
Furthermore, seven-field stereoscopic fundus 
photographs give rise to too many screening 
failures and are therefore not suitable for mass 
screening, especially in a population with a high 
prevalence of cataract. Slit-lamp biomicroscopic 
fundus examination by an ophthalmologist is also 
considered the clinical gold standard and is equally 
effective but not practical for large-scale screening. 
Additionally, clinical verification and validation 
are difficult because of the problem of accurate 
clinical documentation. The detection ability of 
colour fundus photography using a fundus camera 
to detect DR was compared with that of doctors in 
diabetic clinics using ophthalmoscopy. The camera 
detection rate was 4 times higher through undilated 
pupils and more than twice as high through dilated 
pupils.36 Although improved detection rates by 
ophthalmoscopy may improve clinical detection or 
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diagnosis of DR, ophthalmoscopy can easily overlook 
signs of early DR in a busy diabetic clinics.36 
 Various studies have compared single-field 
and two-field screening retinal photographs to 
seven-field stereo photographs.37-40 Single-field 45° 
photographs centred at the fovea, when compared 
with seven-field photographs, had a sensitivity of 74% 
to 86% and specificity of 92% to 95%.37,38 Some other 
studies have shown high sensitivity and specificity to 
detect DR using two-field fundus photographs.39,40 
Two-field 45° to 50° photographs consist of images 
covering the temporal area including the macula 
and optic disc and the second-field covering the 
nasal area including the optic disc (Fig 2). Two-field 
photography has the advantage of detecting DR 
in the nasal retina that could otherwise have been 
missed by single-field photography. 
 The ENSP for diabetic eye disease in the UK 
developed a screening protocol for DR using non-
stereoscopic 45°, two-field fundus photography 
(centred at the macula and optic disc).26,41 Other 
studies have also utilised single- or three-field digital 
fundus photography as a screening tool for DR 
screening.42,43 
 Recently, ultrawide field fundus imaging 
(UWFI) has shown that a 100° to 200° field view of 
the retina can be acquired without pupil dilatation 
(Optos P200MA and Optos P200C imagers; Optos, Fife, 
UK) [Fig 3]. It has the benefits of reducing ungradable 
images, increasing disease detection, and shortening 
image evaluation times.44,45 Since it can detect more 
retinopathy and can detect other peripheral retinal 
pathology, such as retinal detachment and ocular 
tumours, UWFI provides a more ‘complete’ retinal 
examination. Although the image quality of the photo 
is not as good as traditional fundus photography, it 
is gradually improving. It is also very expensive and 
there is colour distortion of the images. With further 
FIG 1.  Seven standard fields of colour fundus photography 
shown in an ultrawide field fundus image (Optos image)
FIG 2.  Two-field fundus photographs of the right eye of a 
patient with diabetic retinopathy 
Centred at (a) fovea and (b) optic disc
FIG 3.  Ultrawide field fundus imaging (Optos image) of the 
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advancements, it may play a role in DR screening in 
the future. 
 Another recent technique, cell phone–based 
technique, has been used in which a handheld 
condensing lens paired with a smartphone camera 
can capture images at low cost.46
Methods used in screening programmes
Several countries have implemented national 
screening programmes including Iceland, ENSP 
in the UK, and the OPHDIAT (a telemedical 
network screening system for DR) in France.47-49 In 
the OPHDIAT programme, fundus photographs 
are first taken with non-mydriatic cameras at 
satellite screening centres by technicians before 
they are transferred via a telemedicine network to 
ophthalmologists for grading.49 In India, similar 
telescreening is being carried out for DR in South 
India, in which 45° single-field digital fundus 
photographs are taken and images transmitted 
digitally for grading by retina specialists.50 In the 
UK, DR graders are not medically trained but they 
undergo vigorous training by ophthalmologists and 
have to carry out a minimum number of grading 
episodes. There are also very stringent quality 
control processes, top-up training, and revalidation 
processes in place to guarantee quality. Once 
patients enter the screening programme, most are 
not required to undergo clinical examination by an 
ophthalmologist unless in cases of STDR or if there 
are ungradable fundus photographs or there is any 
other eye disease that warrants management by an 
ophthalmologist. 
 There is an additional role for general 
practitioners, diabetic nurses, dieticians, and 
others in a DR-related programme, such as the risk 
assessment and management programme (RAMP) 
in the Hospital Authority, Hong Kong. The RAMP is 
a primary health care programme that aims to screen 
patients for chronic systemic diseases including, in 
particular, hypertension and DM including DR.51 
Type 2 DM is a disease of multiple aetiologies in 
which both genetic and environmental factors, 
particularly lifestyle, play a significant role. Lifestyle 
modification is therefore important. The RAMP in 
Hong Kong tries to implement a comprehensive 
package by being holistic—screening for renal 
diseases, examining feet and eyes, monitoring blood 
pressure and other cardiovascular risk factors, and 
educating patients about lifestyle modification. 
The RAMP programme in Hong Kong has been 
successful in controlling HbA1c and blood pressure 
in many subjects and should help to reduce the 
incidence, prevalence, and severity of DR.52 
 Thus, DR screening can be effectively 
performed by ophthalmologists, optometrists, or 
specially trained graders, and other professionals 
play an important part in its wider aspects.
Classification of diabetic retinopathy in 
screening programmes 
The most commonly adopted clinical classification of 
DR is NPDR and PDR. From a screening perspective, 
however, DR is best classified as (1) STDR or vision-
threatening diabetic retinopathy (VTDR) or (2) non-
STDR (or non-VTDR), as STDR warrants referral 
to an ophthalmologist for further management 
while patients with non-STDR can remain in the 
screening programme for further monitoring. Yau 
et al6 highlighted the methods of screening and DR 
grading used in various clinical studies and found 
that most studies use ETDRS and its modification or 
the AAO International Clinical Diabetic Retinopathy 
Disease Severity Scale. Using this classification, DR 
severity is categorised as NPDR (levels 20-53) or 
PDR (≥level 60). For diabetic macular oedema, there 
is more diversity. Some studies consider diabetic 
macular oedema to be present if there is retinal 
thickening within one disc diameter of the centre of 
the macula or if there is a history of macular oedema 
with a history of photocoagulation.6 Other studies 
consider the presence of macular oedema if there 
are hard exudates within one disc diameter of the 
macula or in addition to hard exudates, presence of 
microaneurysm and blot haemorrhage within one 
disc diameter from the foveal centre or the presence 
of focal photocoagulation scars in the macular 
area.53,54 
 The ENSP grading system has grades of no DR 
(R0), mild NPDR (R1), pre-PDR (R2) that includes 
moderate and severe NPDR grades, and PDR (R3) 
[Table 1].55 Maculopathy is said to be present when 
there is hard exudate within one disc diameter 
of the centre of the fovea or microaneurysm or 
dot haemorrhage within one disc diameter of the 
centre of fovea in the presence of visual acuity of 
≤6/12 in the absence of any other obvious cause.55 
The screening outcomes in ENSP include: annual 
screening, referral to an ophthalmologist (for pre-
PDR, which could be moderate or severe NPDR, 
and maculopathy), and fast-track referral (for PDR). 
Although there are different DR classifications, most 
can be converted using a conversion table (Table 2).56 
Systematic diabetic retinopathy 
screening in Hong Kong
Screening procedure
Diabetes is prevalent in Hong Kong with an estimated 
10% of the population afflicted.57 As previously 
described, the Hospital Authority, the major 
public health care provider in Hong Kong, started 
a multidisciplinary RAMP for patients receiving 
DM care in primary care out-patient clinics known 
as general out-patient clinics. All enrolled patients 
in RAMP undergo comprehensive screening for 
diabetic complications including systematic DR 
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screening, following the ENSP guideline, which was 
started in Hong Kong in 2010. As well as RAMP 
attempting to educate and modify the patient risk 
factors such as blood sugar level (HbA1c), blood 
pressure, blood lipids, body weight and smoking 
habit, patients receive treatment from doctors and 
further counselling from nurses about the results of 
tests including the retinopathy result. 
 The DR screening procedure consists of 
checking habitual and pinhole visual acuity in 
each eye using an ETDRS chart. Pupils are dilated 
and non-stereoscopic digital colour retinal fundus 
photographs are taken for each patient: two 
photographs are taken for each eye—one centred at 
the macula and the other centred at the optic disc. 
Grading procedure in diabetic retinopathy 
screening in risk assessment and 
management programme  in Hong Kong
Based on the ENSP, all fundus photographs are graded 
on the digital monitors with a spatial resolution 
of 1024 x 768 pixels, by trained optometrists and 
an ophthalmologist, for presence/absence and 
severity of DR.26,55 The fundus photographs undergo 
TABLE 1.  Grading of diabetic retinopathy55*




R2 Pre-proliferative Venous beading
Venous loop or reduplication
Intraretinal microvascular abnormality 
Multiple deep, round, or blot haemorrhages, and hard exudates
Cotton wool spots in addition to the above features
R3 Proliferative New vessels on disc
New vessels elsewhere
Preretinal or vitreous haemorrhage
Extensive fibrovascular proliferation
Preretinal fibrosis ± tractional retinal detachment
Maculopathy M - Exudate within 1 DD of centre of fovea
Circinate or group of exudates within the macula
Retinal thickening of ≤1 DD of centre of fovea
Any microaneurysm or haemorrhage within 1 DD of centre of fovea only if VA ≤6/12
Photocoagulation P - Focal or scatter laser scars
Other lesions OL - Non-diabetic lesions as ARMD
Unclassifiable U Ungradable For example, if media opacity, poor photographs
Abbreviations: ARMD = age-related macular degeneration; DD = disc diameter; VA = visual acuity
* Sight-threatening diabetic retinopathy includes R2, R3, M, presence of focal or scatter laser scars
TABLE 2.  Different classifications of diabetic retinopathy56
ETDRS NSC (UK) AAO RCOphth
10 None R0 none No apparent retinopathy None 
20 Microaneurysms only R1 background Mild NPDR Low risk 
35 Mild NPDR - Moderate NPDR -
43 Moderate NPDR R2 pre-proliferative - High risk 
47 Moderately severe NPDR - - -
53 A-D severe NPDR - Severe NPDR -
53 E very severe NPDR - - -
61 Mild PDR R3 proliferative PDR PDR
65 Moderate PDR - - -
71,75 High-risk PDR - - -
81,85 Advanced PDR - - -
Abbreviations: AAO = American Academy of Ophthalmology; ETDRS = Early Treatment Diabetic Retinopathy Study; NPDR = 
non-proliferative diabetic retinopathy; NSC (UK) = National Screening Committee (United Kingdom); PDR = proliferative diabetic 
retinopathy; RCOphth = Royal College of Ophthalmologists
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grading by a primary grader, secondary grader, and 
arbitration grader as per ENSP. Fundus photographs 
that are not assessable are considered as ungradable. 
Patients with STDR (grades R2, R3, maculopathy, and 
ungradable) are referred to specialist ophthalmology 
clinics of the Hospital Authority for further 
management. By applying the Icelandic model, 
patients with grades R0 or R1 are usually scheduled 
for their next screening appointment in 12 months 
or later unless they are considered at high risk for 
STDR, based on risk factors including HbA1c and 
blood pressure, in which case, they will be screened 
at a shorter screening interval. Some RAMP clinics 
use the Icelandic model as a reference to stratify the 
individual risk of STDR based on the level of risk 
factors. 
Grader requirements and quality assurance
The graders undergo a structured training 
programme to identify different features of DR, 
periodic assessments, and continuous monitoring 
of grading performance. The graders are required 
to achieve and maintain sensitivity of ≥95% and 
specificity of ≥85% at all levels of grading. For quality 
assurance, a set of images were sent to an international 
DR grading centre, the Ophthalmic Reading Centre, 
Royal Liverpool University Hospital, Liverpool, UK, 
and the grades given were compared with those 
given by the local Hong Kong graders. There was a 
high level of agreement between the local graders 
and those from the international grading centre 
(unpublished data).
 This screening system in Hong Kong has the 
advantage of taking digital fundus photographs, 
which is feasible, affordable in terms of time and 
cost, reproducible, and allows a relatively easy 
grading process. The major challenge in this method 
is the number of referrals generated—particularly for 
patients with maculopathy. In ENSP, patients who 
have a single-dot haemorrhage or exudate close to 
the fovea are referred to the specialist ophthalmology 
clinic. Most of these patients, particularly mild 
cases who do not have clinically significant macular 
oedema, do not require treatment or intervention. 
In addition, patients with grade R2, which includes 
grades of moderate and severe NPDR, may or may 
not need immediate treatment. Nevertheless, the 
system used in Hong Kong is cautious in that the 
patients with STDR who require treatment will be 
identified earlier rather than later. 
Prevalence of diabetic retinopathy/ 
sight-threatening diabetic retinopathy  
from systematic screening 
From August 2010 to March 2014, a total of 262 661 
screening episodes were performed with a total 
number of 174 532 patients receiving DR screening. 
The prevalence of any DR at first screening 
was 39% (68 058/174 532) and of STDR 9.8% 
(17 116/174 532).58 
The future of diabetic retinopathy 
screening 
Screening of DR is currently performed by 
trained professionals, such as ophthalmologists, 
optometrists, or specially trained graders. Since 
it requires screening of large populations and is 
time-consuming, the role of automated grading is 
currently being explored. In this, a computer system 
uses image processing and pattern recognition 
techniques to detect the lesions of DR. The pattern 
recognition consists of two distinct methods: the 
digital image processing method and the neural 
network method. The image processing method 
is suitable for detecting and counting early lesions 
of DR such as haemorrhages, microaneurysms, 
hard exudates, and cotton wool spots. The neural 
network method is suitable for solving pattern 
recognition problems such as lesion patterns of 
various stages of severity of DR; thus the neural 
network method is helpful in grading DR.59 Results 
from computer-aided analysis of the retina or 
automated analysis of diabetic subjects, based on 
the appearance of blood vessels in their ocular 
fundus, are encouraging.60,61 An internet-based 
tele-ophthalmology system could correctly identify 
clinically significant macular oedema and PDR based 
on Joint Photographic Experts Group–compressed 
stereoscopic photographic files when compared 
with standard ETDRS-graded stereoscopic slide 
film photography.62 Researchers are now focusing 
on automated diagnosis of retinopathy by content-
based image retrieval that is the process of retrieving 
related images from a large database collection based 
on their pictorial content.62 
Use of optical coherence 
tomography in screening
Optical coherence tomography (OCT) provides high-
resolution in-vivo imaging of the different cellular 
layers of the macula (Fig 4).25 It is an important 
non-invasive procedure that has revolutionised the 
management of diabetic macular oedema in a way 
that helps to assess and monitor macular thickness, 
monitor macular oedema, identify vitreomacular 
traction and other forms of macular abnormalities 
in patients with diabetic macular oedema.25,63 
Classification by OCT of diabetic macular oedema 
helps to objectively quantify and monitor the 
severity of macular oedema (Table 3).63-65 In the 
DR screening programmes using non-stereoscopic 
digital retinal photos, the presence of maculopathy 
is judged using 2-dimensional fundus photographs 
and many cases identified in this way do not warrant 
treatment. Recently ENSP has started introducing 
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OCT as a screening tool for maculopathy at their 
screening sites (unpublished data).
Conclusion
This review has summarised the recommendations 
and methods of DR screening adopted in various 
countries globally and in Hong Kong. Development 
of low-cost cameras with integration of DR screening 
in public health care programmes could facilitate the 
availability of DR screening to populations of different 
income groups in various countries, particularly in 
developing countries. Sustainability of a quality-
assured screening programme, ensuring that patients 
are compliant with appropriate screening intervals 
and treatment, is one of the greatest challenges that 
can be overcome by educating the population and 
empowering primary eye care workers and health 
care workers. Continued efforts are required by all 
eye care professionals.
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